TRAF2 and cancer: Mutations in various upstream regulators (TRAF2, TRAF3, cIAP1&2, CD40) lead to increased stability of NIK and subsequent activation of the noncanonical NF-kB pathway, and this mechanism of activation appears to be important for different cancer types including DLBC and lung cancer (52).